All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Sleeping Beauty (SB) transposon, a type of nonviral integrative vectors, provides an alternative to modify primary T cells. Creative biolabs has developed SB transposon CAR vector pSBCAR1 AFP (5F11) h(28ζ), which is constructed for the engineering of T cells to target human AFP. The T cells are genetically modified through transduction with a nonviral vector expressing scFv of anti-AFP antibody linked to CD28 and CD3ζ signaling domains. And the vector product was designed for the treatment of Liver cancer.
CAR Construction : Fig.1 T cell cytotoxicity of LAN-1 cells in the presence of 5F11-BsAbs. T cell cytotoxicity of LAN-1 cells labelled with 51Cr was assayed in the presence of increasing concentrations of 5F11-BsAbs. Specific lysis was measured by 51Cr release in supernatant counted by a γ-counter. Cheng, M., Ahmed, M., Xu, H., & Cheung, N. K. (2015). Structural design of disialoganglioside GD2 and CD3-bispecific antibodies to redirect T cells for tumor therapy. International journal of cancer, 136(2), 476–486. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-AFP (5F11) h(CD28-CD3ζ) CAR, pSBCAR1 (CAR-SB-LX0009). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION